Novavax Says Anticipating Booster Approval After FDA Review

Novavax said it is anticipating emergency approval in the US for its Covid-19 vaccine to be used a booster in people aged 18 and older, following completion of a review by the FDA.

• Novavax did not give a timeline
• Conducting ongoing trials
• “Preclinical data has indicated that our vaccine induces immune response against Omicron variants, including BA.4/5”

NOTE

• Novavax Inc. fell 5.8% to $31.11 as of 2:16 p.m. New York time
  • The average 12-month price target of $151.20 is 386.0% above the current price
  • 5 buys, 2 holds, 1 sells

To contact the reporter on this story:
Zac Fleming in ...